Small molecule keeps new adult neurons from straying, may be tied to schizophrenia
A small stretch of ribonucleic acid called microRNA could make the difference between a healthy adult brain and one that’s prone to disorders including schizophrenia.
Scientists at the Salk Institute discovered that miR-19 guides the placement of new neurons in the adult brain, and the molecule is disrupted in cells from patients with schizophrenia.
The findings, published in the journal Neuron on July 6, 2016, pave the way toward a better understanding of how the adult brain controls the growth of new neurons and how it can go wrong.
Salk Professor Rusty Gage, first author Jinju Han and their colleagues found that levels of miR-19 changed more than levels of any other microRNA when precursors to new brain cells in these areas (called neural progenitor cells) were coaxed to become neurons in the adult brain. The researchers went on to show that when miR-19 was blocked in neural progenitor cells, levels of RNA corresponding to a gene called Rapgef2 were altered. Moreover, new neurons did not migrate to the correct areas of the brain.
Because the incorrect migration of new brain cells has been implicated in neuropsychiatric disorders like schizophrenia, Gage’s group next analyzed the levels of miR-19 and Rapgef2 in neural progenitor cells that had been created by reprogramming skin cells from schizophrenic patients. Although the patients had no mutations in the gene for Rapgef2, they had high levels of miR-19 that corresponded with low levels of both the RNA and protein for Rapgef2. The team is now studying the role of miR-19 in mouse models of schizophrenia, as well as looking at cells from broader cohorts of human patients.
Read News ReleaseFeatured Stories
Seeds of change: The Harnessing Plants Initiative is scaling a new kind of crop that could save the future of farming—and the planetFarmers and plant biologists are linking arms to build more sustainable, resilient agriculture. Salk scientists are working to enhance plants' natural ability to capture carbon to clean our air and restore environmental stability—all while maintaining productivity for growers.
The day polio met its match: Celebrating 70 years of the Salk vaccineSeventy years ago, on April 12, 1955, the polio vaccine developed by Jonas Salk and his colleagues was officially declared “safe, effective, and potent”—a moment heralded as a triumph of medicine over one of the most feared diseases of the 20th century. On this milestone anniversary, it's crucial to remember that fear, and learn from this historic public health success.
50 years of discovery: Professor Tony Hunter’s half-century legacy at SalkTony Hunter first arrived at the Salk Institute in 1971 as a postdoctoral trainee from the University of Cambridge. Four years later, he officially joined the Institute as an assistant professor and cancer biology pioneer.
Pallav Kosuri: Making magic out of moleculesA physicist-turned-bioengineer, Kosuri is developing nanoscale technologies that are on their way to transforming how we diagnose and treat diseases. Kosuri’s lab is using DNA to create a suite of biosensors, diagnostic tools, and drug delivery systems.
Suzanne Page: Uprooting, replanting, and blooming againIn October 2024, the Salk Institute named Suzanne Page as its new Vice President and Chief Operating Officer. Page has lived and traveled all over the country, developing a strong background in research operations, finance, and legal in the for-profit and nonprofit sectors—leading her to "manifest" her role at Salk.
Irene López Gutiérrez: After every storm comes sunshine—and scienceRainy winter weather in Gutiérrez's seaside hometown in Spain led to long days indoors, where she found a science television show that inspired an entire life of education and research that eventually brought her to Salk. Today, she works in Professor Susan Kaech's lab studying Alzheimer's disease.
Michelle Chamberlain named Salk’s new Vice President of External RelationsMichelle Chamberlain assumed the role on April 2, where she will serve on Salk's Executive Leadership Team and oversee all fundraising efforts, communications, community engagement, education outreach programs, foundation relations, and stewardship activities.
Trustee Richard A. Heyman donates $4.5 million to enable early-stage innovative researchRichard A. Heyman, a member of the Salk Institute’s Board of Trustees, and his wife, Anne Daigle, have donated $4.5 million to establish the new Richard A. Heyman Collaborative Innovation Fund to support Institute faculty on collaborative, early-stage studies aimed at big, bold questions.